Nicotine enhances the depressive actions of A beta 1-40 on long-term potentiation in the rat hippocampal CA1 region in vivo

J Neurophysiol. 2003 Jun;89(6):2917-22. doi: 10.1152/jn.00996.2002. Epub 2003 Jan 22.

Abstract

Hippocampal long-term potentiation (LTP) is a form of synaptic plasticity used as a cellular model of memory. Beta amyloid (A beta) is involved in Alzheimer's disease (AD), a neurode-generative disorder leading to cognitive deficits. Nicotine is also claimed to act as a cognitive enhancer. A beta is known to bind with high affinity to the alpha 7-nicotinic acetylcholine receptor (nAChR). Here we have investigated the effect of intracerebroventricular (i.c.v.) injection of the endogenous peptide A beta 1-40 on LTP in area CA1 of urethananesthetized rats. We also examined the effect of A beta 12-28 (i.c.v.), which binds with high affinity to the alpha 7-nAChR and the specific alpha 7-nAChR antagonist methyllycaconitine (MLA) on LTP. We found that A beta 12-28 had no effect on LTP, whereas MLA depressed significantly LTP, suggesting that activation of the alpha 7-nAChR is a requirement for LTP. Within the in vivo environment, where other factors may compete with A beta 12-28 for binding to alpha 7-nAChR, it does not appear to modulate LTP. To determine if the depressive action of A beta 1-40 on LTP could be modulated by nicotine, these agents were also co-applied. Injection of 1 or 10 nmol A beta 1-40 caused a significant depression of LTP, whereas nicotine alone (3 mg/kg) had no effect on LTP. Co-injection of nicotine with A beta 1-40 1 h prior to LTP induction caused a further significant depression of LTP compared with A beta 1-40 alone. These results demonstrate that nicotine enhances the deficit in LTP produced by A beta 1-40. This then suggests that nicotine may exacerbate the depressive actions of A beta on synaptic plasticity in AD.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aconitine / analogs & derivatives*
  • Aconitine / pharmacology
  • Alzheimer Disease / physiopathology
  • Amyloid beta-Peptides / administration & dosage
  • Amyloid beta-Peptides / adverse effects*
  • Animals
  • Electrophysiology
  • Hippocampus / drug effects*
  • Hippocampus / physiology*
  • Hippocampus / physiopathology
  • Injections, Intraventricular
  • Long-Term Potentiation / drug effects*
  • Male
  • Neuronal Plasticity / drug effects
  • Nicotine / adverse effects*
  • Nicotine / pharmacology
  • Nicotinic Agonists / adverse effects*
  • Nicotinic Agonists / pharmacology
  • Nicotinic Antagonists / pharmacology
  • Peptide Fragments / administration & dosage
  • Peptide Fragments / adverse effects*
  • Rats
  • Rats, Wistar
  • Receptors, Nicotinic / physiology

Substances

  • Amyloid beta-Peptides
  • Nicotinic Agonists
  • Nicotinic Antagonists
  • Peptide Fragments
  • Receptors, Nicotinic
  • amyloid beta-protein (1-40)
  • amyloid beta-protein (12-28)
  • methyllycaconitine
  • Nicotine
  • Aconitine